Syremis Therapeutics Overview

  • Year Founded
  • 2025

Year Founded

  • Status
  • Private

  • Latest Deal Type
  • Series A

  • Latest Deal Amount
  • $165M

  • Investors
  • 6

Syremis Therapeutics General Information

Description

Operator of a biopharmaceutical company intended to develop novel medicines that address major unmet needs in mental health care. The company offers a neuropsychiatric drug pipeline rooted in emerging and clinically validated biology, such as muscarinic M1/M4 agonism and next-generation NMDA antagonism, enabling customers to access more effective and better-tolerated treatments for conditions like schizophrenia, major depressive disorder and bipolar depression, ultimately reducing disability, relapse rates and improving quality of life.

Contact Information

Website
www.syremis.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Tel Aviv
  • Israel
Primary Industry
Biotechnology
Vertical(s)
Corporate Office
  • Tel Aviv
  • Israel

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Syremis Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Early Stage VC (Series A) 02-Dec-2025 $165M Completed Pre-Clinical Trials
To view Syremis Therapeutics’s complete valuation and funding history, request access »

Syremis Therapeutics Patents

Syremis Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026202849-A1 Pharmaceutically acceptable salts of n-acetyl-d-valine dextrorphan Pending 28-Mar-2025
WO-2026126144-A1 Xanomeline combinations for treating neurological disorders Pending 12-Dec-2024
WO-2026018155-A1 Combinations of sabcomeline with long-acting non-cns penetrant muscarinic antagonists Pending 16-Jul-2024
WO-2026018154-A1 Combinations of sabcomeline with non-cns penetrant muscarinic antagonists Pending 16-Jul-2024
US-20260102381-A1 Muscarinic agent combinations Pending 16-Jul-2024 A61K31/439
To view Syremis Therapeutics’s complete patent history, request access »

Syremis Therapeutics Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds
Bain Capital Life Sciences Corporate Venture Capital Minority
Dexcel Pharma Corporation Minority
GV Corporate Venture Capital Minority
Pictet Asset Manager Minority
QVT Family Office Family Office Minority
You’re viewing 5 of 6 investors. Get the full list »

Syremis Therapeutics FAQs

  • When was Syremis Therapeutics founded?

    Syremis Therapeutics was founded in 2025.

  • Where is Syremis Therapeutics headquartered?

    Syremis Therapeutics is headquartered in Tel Aviv, Israel.

  • What industry is Syremis Therapeutics in?

    Syremis Therapeutics’s primary industry is Biotechnology.

  • Is Syremis Therapeutics a private or public company?

    Syremis Therapeutics is a Private company.

  • What is Syremis Therapeutics’s current revenue?

    The current revenue for Syremis Therapeutics is .

  • How much funding has Syremis Therapeutics raised over time?

    Syremis Therapeutics has raised $165M.

  • Who are Syremis Therapeutics’s investors?

    Bain Capital Life Sciences, Dexcel Pharma, GV, Pictet, and QVT Family Office are 5 of 6 investors who have invested in Syremis Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process